S&P 500
(0.12%) 5 303.27 points

Dow Jones
(0.34%) 40 004 points

Nasdaq
(-0.07%) 16 686 points

Oil
(-0.10%) $79.98

Gas
(1.37%) $2.66

Gold
(0.81%) $2 437.10

Silver
(4.08%) $32.54

Platinum
(0.93%) $1 100.10

USD/EUR
(-0.03%) $0.919

USD/NOK
(-0.06%) $10.67

USD/GBP
(0.03%) $0.787

USD/RUB
(0.09%) $91.05

Realtime updates for Eli Lilly and Co [LLY.DE]

Exchange: XETRA Sector: Pharmaceuticals Industry: Drug Manufacturers—General

Last Updated17 May 2024 @ 11:35

25% discount on Stockinvest.us - Use code: Podcast

-0.58% € 708.60

Live Chart Being Loaded With Signals

Commentary (17 May 2024 @ 11:35):

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes...

Stats
Today's Volume	2 081.00
Average Volume	4 788.00
Market Cap	673.46B
EPS	€0 ( 2024-04-30 )
Next earnings date	( €1.540 ) 2024-08-07
Last Dividend	€1.130 ( 2023-08-14 )
Next Dividend	€0 ( N/A )
P/E	113.56
ATR14	€0.685 (0.10%)

Volume Correlation

Long: 0.07 (neutral)

Short: -0.43 (neutral)

Signal:(40.141) Neutral

Eli Lilly and Co Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Eli Lilly and Co Correlation - Currency/Commodity

0.11
( neutral )

-0.66
( moderate negative )

0.37
( neutral )

-0.08
( neutral )

-0.63
( weak negative )

-0.13
( neutral )

Eli Lilly and Co Financials

Annual	2023
Revenue:	€34.12B
Gross Profit:	€27.04B (79.25 %)
EPS:	€5.82

FY	2023
Revenue:	€34.12B
Gross Profit:	€27.04B (79.25 %)
EPS:	€5.82

FY	2022
Revenue:	€28.54B
Gross Profit:	€21.91B (76.77 %)
EPS:	€6.93

FY	2021
Revenue:	€28.32B
Gross Profit:	€21.01B (74.18 %)
EPS:	€5.83

Financial Reports:

No articles found.

Eli Lilly and Co Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
€0.980 (N/A)	€0.980 (N/A)	€1.130 (N/A)	€1.130 (N/A)	€1.130 (N/A)	€0 (N/A)	€0 (N/A)	€0 (N/A)	€0 (N/A)	€0 (N/A)

Eli Lilly and Co Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 7.36 - good (73.60%) | Divividend Growth Potential Score: 6.18 - Stable (23.51%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	€0.490	2009-05-13
Last Dividend	€1.130	2023-08-14
Next Dividend	€0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	41	--
Total Paid Out	€27.35	--
Avg. Dividend % Per Year	0.00%	--
Score	3.94	--
Div. Sustainability Score	7.36
Div.Growth Potential Score	6.18
Div. Directional Score	6.77	--

Next Divdend (Est)
(2024-09-05)

€1.166 Estimate 20.00 %

Dividend Stability

0.53 Average

Dividend Score

3.94

Pay Frequency

Quarterly

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.

Top 10 dividend Companies for XETRA

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
HCL.DE	Ex Dividend Junior	2023-08-23	Quarterly	0	0.00%
UNH.DE	Ex Dividend Knight	2023-09-08	Quarterly	0	0.00%
AP2.DE	Ex Dividend Knight	2023-11-22	Quarterly	0	0.00%
LAR.DE	Ex Dividend Knight	2023-09-12	Quarterly	0	0.00%
CHV.DE	Ex Dividend King	2023-08-17	Quarterly	0	0.00%
NTH.DE	Ex Dividend Knight	2023-08-25	Quarterly	0	0.00%
ERCB.DE	Ex Dividend Junior	2023-09-28	Annually	0	0.00%
RLI.F	Ex Dividend Junior	2023-08-17	Annually	0	0.00%
3T70.F	Ex Dividend Knight	2023-08-31	Quarterly	0	0.00%
GXI.DE	Ex Dividend Junior	2023-06-08	Annually	0	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.171	1.500	6.58	9.88	[0 - 0.5]
returnOnAssetsTTM	0.0960	1.200	6.80	8.16	[0 - 0.3]
returnOnEquityTTM	0.535	1.500	5.16	7.74	[0.1 - 1]
payoutRatioTTM	0.688	-1.000	3.12	-3.12	[0 - 1]
currentRatioTTM	1.354	0.800	8.23	6.58	[1 - 3]
quickRatioTTM	0.677	0.800	-0.721	-0.577	[0.8 - 2.5]
cashRatioTTM	0.132	1.500	-0.376	-0.564	[0.2 - 2]
debtRatioTTM	0.410	-1.500	3.17	-4.75	[0 - 0.6]
interestCoverageTTM	15.16	1.000	5.50	5.50	[3 - 30]
operatingCashFlowPerShareTTM	4.06	2.00	8.65	10.00	[0 - 30]
freeCashFlowPerShareTTM	-4.31	2.00	-2.15	-4.31	[0 - 20]
debtEquityRatioTTM	2.05	-1.500	1.817	-2.73	[0 - 2.5]
grossProfitMarginTTM	0.802	1.000	10.00	10.00	[0.2 - 0.8]
operatingProfitMarginTTM	0.237	1.000	7.25	7.25	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.140	1.000	-0.332	-0.332	[0.2 - 2]
assetTurnoverTTM	0.562	0.800	9.59	7.67	[0.5 - 2]
Total Score				7.36

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	113.50	1.000	10.00	0	[1 - 100]
returnOnEquityTTM	0.535	2.50	6.89	7.74	[0.1 - 1.5]
freeCashFlowPerShareTTM	-4.31	2.00	-1.436	-4.31	[0 - 30]
dividendYielPercentageTTM	0.631	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	4.06	2.00	8.65	10.00	[0 - 30]
payoutRatioTTM	0.688	1.500	3.12	-3.12	[0 - 1]
pegRatioTTM	9.14	1.500	10.00	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.102	1.000	9.94	0	[0.1 - 0.5]
Total Score				6.18

Eli Lilly and Co Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Eli Lilly and Co

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

About Live Signals

The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.

The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators

Investing in the stock market involves risk and the value of your investment can fluctuate. The stock market can be affected by a variety of factors, including economic conditions, company performance, and global events. There is no guarantee of profit and you could lose money. Please consider your financial situation, investment goals, and level of risk tolerance before making any investment decisions. Consult with a financial advisor for personalized advice.